<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510233</url>
  </required_header>
  <id_info>
    <org_study_id>IvrInh</org_study_id>
    <nct_id>NCT04510233</nct_id>
  </id_info>
  <brief_title>Ivermectin Nasal Spray for COVID19 Patients</brief_title>
  <official_title>Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global escalation of COVID19 pandemic has put the health care system under pressure with
      urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over
      the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight
      this pandemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ivermectin is a well-known FDA-approved pan antiparasitic drug with high safety profile and
      potential therapeutic effects against COVID 19. It has been previously investigated as an
      antiviral agent. It showed 5000 fold reduction of SARS COV 2 viral RNA in-vitro studies.

      However, some researchers questioned its efficacy in the oral form as very high doses will be
      required to achieve a proper tissue concentration and viricidal effect in the respiratory
      system.

      Our hypothesis is that, since COVID-19 has shown to be particularly damaging to the
      respiratory system, using inhaled forms of Ivermectin will deliver the drug directly to the
      infection site and make it a treatment option.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR of SARS-Cov2 RNA</measure>
    <time_frame>14 days</time_frame>
    <description>Negative PCR result of SARS-Cov2 RNA in COVID19 patients</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ivermectin nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin administered as nasal spray (one ml in each nostril two times daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVID-19 cases will receive standard of care [oxygen via masks or ventilators]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin nasal</intervention_name>
    <description>Ivermectin nasal spray one ml in each nostril two times daily</description>
    <arm_group_label>Ivermectin nasal spray</arm_group_label>
    <other_name>ivermectin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin oral</intervention_name>
    <description>Ivermectin oral (one tablet 6 mg three times daily)</description>
    <arm_group_label>Ivermectin oral</arm_group_label>
    <other_name>ivermectin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>oxygen via masks or ventilators</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate severity who are confirmed to be positive for SARS COV 2.

        Exclusion Criteria:

          -  patients with severe form of COVID-19 or those who are on ventilatory support or those
             with cytokine storm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Okasha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta Univesity faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamal Okasha, PhD</last_name>
    <phone>201140403709</phone>
    <email>okasha70@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahla El-Ashmawy, PhD</last_name>
    <phone>201116721982</phone>
    <email>nahlaelashmawy@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Kamal Mohammed Okasha</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

